Biocon shares in focus after successful results of Yesintek in Phase 3
Shares of Biocon will remain in focus on Monday, March 10, after the company announced that it has achieved positive results from a phase 3 study that compares Yesintek (Biocon Biologics’ biosimilar to Ustekinumab) with reference products. “Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523,…